Broach Lifecare Hospital accepted the resignation of Ms. Urvi Mrunal Hindia as Chief Financial Officer, effective August 31, 2026. The company disclosed the departure to BSE Limited on September 11, 2026, citing personal reasons for her exit.

The firm responded to a query from the exchange regarding its initial corporate announcement dated August 25, 2026. While the resignation event was communicated on time, the actual resignation letter was inadvertently not attached to that disclosure.

Regulatory Compliance Details

Broach Lifecare clarified that there was no delay in disclosing the resignation itself, as the exchange was notified prior to the effective date. However, the supporting document was not submitted within the mandated seven days from the effective date of resignation.

The company assured regulators that internal checks have been strengthened to prevent such omissions in the future. A copy of the resignation letter and disclosures pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, were attached to the reply.

Key Disclosures

Ms. Hindia tendered her resignation on August 24, 2026. The Managing Director, Jaykumar Narendra Vyas, signed the communication to the stock exchange, confirming the cessation of her duties.

Broach Lifecare Hospital reported a sharp rise in revenue for FY26, but profitability contracted significantly as operational costs expanded faster than income. The company’s board approved the financial results on September 5, 2026.

Financial Performance

Revenue from operations grew 88% year-on-year to ₹599.47 lakh in FY26, compared to ₹317.94 lakh in FY25. This growth was driven by increased activity across its cardiac care services. However, total expenses more than doubled to ₹582.62 lakh from ₹250.91 lakh in the previous year.

The surge in costs pressured the bottom line, resulting in a net profit of ₹8.68 lakh, a decline of 84% from the ₹53.59 lakh recorded in FY25. Earnings per share (basic and diluted) fell to ₹0.14 from ₹0.98 in the prior fiscal year.

Operational Highlights

The revenue mix showed significant growth in key segments:

• Inpatient department (IPD) income rose to ₹353.92 lakh from ₹251.53 lakh.
• Outpatient department (OPD) income increased to ₹35.43 lakh from ₹21.40 lakh.
• Radiology and pathology revenue surged to ₹51.51 lakh from ₹1.81 lakh.
• Net sales grew to ₹158.62 lakh from ₹40.87 lakh.

Employee benefit expenses were the largest cost component at ₹115.70 lakh, up from ₹72.98 lakh. Other expenses, including consultancy charges of ₹126.24 lakh and professional charges of ₹35.02 lakh, also contributed to the higher expense base.

Corporate Governance and AGM Details

The board appointed M/s. Rahul S. Mithaiwala & Co. as Secretarial Auditor for five years, subject to member approval. The company notified BSE Limited of these outcomes pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has scheduled its 3rd Annual General Meeting (AGM) for Wednesday, September 30, 2026, at 11:30 am via Video Conferencing or Other Audio-Visual Means. This meeting will address the Annual Report for Financial Year 2025-26. Members whose email addresses are not registered with the Company, Registrar and Share Transfer Agent, or Depository Participants have been sent letters providing web-links to access the Annual Report, pursuant to Regulation 36(1)(b) of the SEBI Listing Regulations.

Key dates for shareholders include:

• Cut-off date for voting eligibility: September 23, 2026
• E-voting commencement: September 27, 2026, at 9:00 am
• E-voting end: September 29, 2026, at 5:00 pm
• AGM date: September 30, 2026, at 11:30 am via Video Conferencing

Jaykumar Narendra Vyas, Managing Director, signed the intimation letter. The company’s registered office is located in Bharuch, Gujarat.